Rite Aid (RAD) May Comps Rose 3.5%; Guides Q1 EPS Below Consensus
Get Alerts RAD Hot Sheet
EPS Growth %: +100.0%
Financial Fact:
Selling, general and administrative expenses: 1.78B
Today's EPS Names:
SHIM, KOD, HEWA, More
Join SI Premium – FREE
Rite Aid (NYSE: RAD) announced sales results for May. The Company also provided preliminary estimated financial results for the quarter ended May 31, 2014 and updated its outlook for 2015 fiscal year.
Monthly Sales
For the five weeks ended May 31, 2014, same store sales increased 3.5 percent over the prior-year period. May front-end same store sales increased 0.5 percent. Pharmacy same store sales, which included an approximate 156 basis points negative impact from new generic introductions, increased 5.0 percent. Prescription count at comparable stores increased 3.2 percent over the prior-year period.
Total drugstore sales for the five-week period increased 2.5 percent to $2.484 billion compared to $2.423 billion for the same period last year. Prescription sales accounted for 68.0 percent of drugstore sales, and third party prescription sales represented 97.4 percent of pharmacy sales.
Quarterly Sales
Same store sales for the 13-week period ended May 31, 2014 increased 3.1 percent over the prior-year period. Front-end same store sales were flat compared to the prior-year period while pharmacy same store sales increased 4.6 percent. Prescription count at comparable stores increased 2.3 percent over the prior-year period.
Total drugstore sales for the 13 weeks ended May 31, 2014 increased 2.6 percent with sales of $6.425 billion compared to $6.264 billion for the same period last year. Prescription sales represented 68.4 percent of total drugstore sales, and third party prescription sales represented 97.4 percent of pharmacy sales.
Preliminary Financial Results
Although results for the quarter ended May 31, 2014 will not be released until June 19, 2014, the Company expects Adjusted EBITDA (which is reconciled to net income on the attached table) for the quarter to be between $275 million and $285 million, net income to be between $35 million and $45 million and income per diluted share to be $.04. Based on pharmacy margin trends, particularly in May, the Company expects its results for Adjusted EBITDA to trail the results for the previous year’s first quarter due primarily to higher-than-expected drug costs resulting from a delay in realizing the level of expected generic purchase price reductions and a greater-than-expected reduction in reimbursement rates. Rite Aid’s actual financial results for the quarter ended May 31, 2014 have not been finalized by management, and as a result, Rite Aid’s actual results may differ from the estimates above. The Company undertakes no obligation to update future quarterly periods prior to its regularly scheduled earnings release.
*** The Street sees Q1 EPS of $.08.
Revised Outlook for Fiscal 2015
Based on the expected results for the quarter ended May 31, 2014 and the generic purchase price reductions that are expected for the remainder of the year, the company is updating its Fiscal 2015 guidance for Adjusted EBITDA, net income and income per diluted share. Adjusted EBITDA (which is reconciled to net income on the attached table) is expected to be between $1.275 billion and $1.350 billion. Net income for fiscal 2015 is expected to be between $298 million and $408 million or income per diluted share of $.30 to $.40. The Company’s guidance for sales, same store sales increases and capital expenditures remain unchanged.
*** The Street sees FY15 EPS of $.39.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Recruit Holdings Co., Ltd (6098:JP) (RCRUY) PT Raised to JPY7,800 at Jefferies, 'emerged stronger since the last earnings season'
- NRx Pharmaceuticals (NRXP) Reports Prelim FY23 Results
- Hyundai Mobis Co Ltd. (012330:KS) PT Raised to KRW340,000 at HSBC
Create E-mail Alert Related Categories
Guidance, Hot Corp. News, Hot Guidance, Retail SalesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!